FDA’s June 2026 guide explicitly includes EX in its cross-study and cross-domain naming-consistency guidance for drugs and metabolites.
ReviewedEvidence1 sourceSectionWriting & Style
Quick answer
FDA’s June 2026 guide says drug and metabolite naming should, to the extent possible, remain consistent across clinical/nonclinical studies and across domains, explicitly including TS, EX, PC, and PP.
Key details
Core IssueFDA’s June 2026 guide explicitly includes EX in its cross-study and cross-domain naming-consistency guidance for drugs and metabolites.
Registerscholarly, professional, or research/report writing
Important caveats
Scope Boundary
This is current FDA technical-conformance guidance for electronic study-data submissions; recheck the current FDA guide, supported standards, Data Standards Catalog, and eCTD specifications before relying on version-sensitive requirements.
Further guidance
Content
Keep drug and metabolite names aligned, to the extent possible, across studies and relevant domains including EX, rather than inventing domain-specific naming variants.
Purpose
Support reviewer navigation and cross-domain matching of the same drugs and metabolites without turning the broader naming-consistency rule into unsupported EX-specific data-model requirements.
Sources and evidence
Sources are shown with the role they play in this guide. Historical or style-sensitive claims are kept within the evidence boundary described above.
FDA’s June 2026 guide says the AE domain should include all adverse events unless an indication-specific technical specification says otherwise and asks for the criterion supporting a serious-event flag.
FDA’s June 2026 guide describes the DD (Death Details) domain for supplemental information collected when a death occurs and expects consistency with relevant AE-domain death variables.
FDA’s June 2026 conformance guide says screen failures, when provided, should be represented as a DM record with specified planned/actual arm fields left blank.
FDA’s June 2026 guide gives DS-domain handling for multiple disposition events, including use of EPOCH or DSSCAT and a specific final-record convention for death.
FDA’s June 2026 guide explicitly calls for the DV domain in submissions containing protocol-deviation data and identifies review-oriented variables beyond CDISC-required fields.
FDA’s June 2026 guide gives a direct placement rule for viral-load results in standardized clinical study data: place them in the MB (Microbiology) domain.
